Filtered By:
Source: Cancer Control
Cancer: Adenocarcinoma
This page shows you your search results in order of date.
Order by Relevance | Date
Total 681 results found since Jan 2013.
Taxane-Based Chemotherapy Is Effective in Metastatic Appendiceal Adenocarcinoma
Oncologist. 2023 Sep 20:oyad263. doi: 10.1093/oncolo/oyad263. Online ahead of print.ABSTRACTAppendiceal cancer is a rare, orphan disease with no therapies currently approved by the FDA for its treatment. Given the limited data regarding drug efficacy, these tumors have historically been treated with chemotherapy designed for colon cancer. However, an overwhelming body of molecular data has demonstrated that appendiceal adenocarcinoma is a distinct entity with key molecular differences from colon cancer, notably rare APC mutation. Recognizing that APC loss-of-function is thought to contribute to taxane resistance and that t...
Source: Cancer Control - September 22, 2023 Category: Cancer & Oncology Authors: Julia Dansby Aditya More Mohammad Zeineddine Abdelrahman Yousef Alisha Bent Farshid Dayyani Robert Wolff Michael Overman John Paul Shen Source Type: research
Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial
DISCUSSION: This trial will help define the best neoadjuvant treatment sequence for borderline resectable PDAC and aims to evaluate if a total neoadjuvant treatment integrating iHD-SBRT improves the patients' oncological outcomes.TRIAL REGISTRATION: The study was registered at ClinicalTrails.gov (NCT05083247) on October 19th, 2021, and in the Clinical Trials Information System (CTIS) EU CT database (2022-501181-22-01) on July 2022.PMID:37735634 | DOI:10.1186/s12885-023-11327-x
Source: Cancer Control - September 22, 2023 Category: Cancer & Oncology Authors: Christelle Bouchart Julie Navez Ivan Borbath Karen Geboes Timon Vandamme Jean Closset Luigi Moretti Pieter Demetter Marianne Paesmans Jean-Luc Van Laethem Source Type: research
Down-regulation of interleukin-2 predicts poor prognosis and associated with immune escape in lung adenocarcinoma
Conclusion: Our results indicate that down-regulation of IL2 predicts poor prognosis and is associated with immune escape in LUAD, and IL2 could serve as a potential novel prognostic biomarker of LUAD.PMID:37731383 | DOI:10.1177/03946320231202748
Source: Cancer Control - September 21, 2023 Category: Cancer & Oncology Authors: Yongwang Hou Baoli Xiang Zhicong Yang Jiangmin Liu Dandan Xu Lina Geng Minghua Zhan Yuhuan Xu Bin Zhang Source Type: research
Tetrahydrobiopterin from cyanide-degrading bacterium Bacillus pumilus strain SVD06 induces apoptosis in human lung adenocarcinoma cell (A549)
Biotechnol Appl Biochem. 2023 Sep 20. doi: 10.1002/bab.2509. Online ahead of print.ABSTRACTTetrahydrobiopterin (BH4) is an essential biological cofactor and a derivative of pterin which is considered potent anticancer agents. In continuation of our previous study on the identification of BH4 from cyanide-degrading Bacillus pumilus, the present study focuses on evaluating the anticancer properties of BH4 on A549, a human lung adenocarcinoma. Anticancer activity analysis shows that BH4 inhibited A549 cell growth after 24 h of incubation with 0.02 mg/mL. In acridine orange/ethidium bromide staining, BH4-treated A549 cells sho...
Source: Cancer Control - September 21, 2023 Category: Cancer & Oncology Authors: Ramasamy Mahendran Sanjay Prasad Selvaraj Anand Raj Dhanapal Sabna Bhaskaran Sarasa Beutline Malgija Mathias Bency Thankappan Daniel Raja Femil Selta Palanivel Naveen Rhenghachar Poorani Navaneethan Sundhar Mamatha M Pillai Rajendran Selvakumar Chih-Yang Source Type: research
Endometrial adenocarcinoma recurring in the lung: impact of molecular profile and role of local therapies on prognosis
CONCLUSION: Although few patients will benefit from local treatment (stereotactic body radiation therapy or resection) after a recurrence involving the lung, local therapies might be considered as an option in oligometastatic lung recurrences as they achieve high local control rates and better oncological outcomes than systemic treatment alone.PMID:37726197 | DOI:10.1136/ijgc-2023-004534
Source: Cancer Control - September 19, 2023 Category: Cancer & Oncology Authors: Ana Luzarraga Aznar Vicente Bebia Carlos L ópez-Gil Alexandra Giraldo M P Montoya Ramona Verges Alberto Jauregui Josep Castellvi Assumpci ó Pérez-Benavente Eva Col ás Antonio Gil-Moreno Silvia Cabrera Source Type: research
Associations between longer leukocyte telomere length and increased lung cancer risk among never smokers in urban China
CONCLUSIONS: Longer pre-diagnostic leukocyte telomere length is associated with increased lung cancer risk among never smokers.IMPACT: Our findings firmly support the role of longer telomeres in lung carcinogenesis.PMID:37721487 | DOI:10.1158/1055-9965.EPI-23-0881
Source: Cancer Control - September 18, 2023 Category: Cancer & Oncology Authors: Jason Yy Wong Xiao-Ou Shu Wei Hu Batel Blechter Jianxin Shi Kevin Wang Richard Cawthon Qiuyin Cai Gong Yang Mohammad L Rahman Bu-Tian Ji Yutang Gao Wei Zheng Nathaniel Rothman Qing Lan Source Type: research
Controversies in the surgical management of esophageal adenocarcinoma
J Gastrointest Oncol. 2023 Aug 31;14(4):1919-1926. doi: 10.21037/jgo-22-713. Epub 2023 Aug 30.ABSTRACTThe incidence of esophageal adenocarcinoma (EAC) has risen dramatically over the last decade. Over this same period, our understanding and treatments have been revolutionized. Just over a decade ago, the majority of patients with locally advanced esophageal cancer went directly to surgery and our overall survival was bleak. Our current strategy for locally advanced esophageal adenocarcinoma is a multi-disciplinary approach. This approach consists of chemotherapy plus or minus radiation followed by surgical resection follow...
Source: Cancer Control - September 18, 2023 Category: Cancer & Oncology Authors: Stephanie G Worrell Daniela Molena Source Type: research
Effect of Yifei Qinghua Granule on the Tumor Microenvironment in Lung Cancer by Regulating the Inflammatory Pathway
Cell Mol Biol (Noisy-le-grand). 2023 Aug 31;69(8):118-124. doi: 10.14715/cmb/2023.69.8.18.ABSTRACTTo investigate the mechanism of action of inflammatory molecules regulating the tumor microenvironment and anti-tumor through Yifei Qinghua granules and phloroglucinol-containing serum intervening in the changes of tumor microenvironment in vitro in the co-culture of lung cancer cells and bone marrow cells. A549 lung adenocarcinoma cell line and ST2 bone marrow stromal cell line were selected and a transwell chamber was used to establish the co-culture system of the two kinds of cells. They were divided into normal saline, phl...
Source: Cancer Control - September 16, 2023 Category: Cancer & Oncology Authors: LiHong Zhang Zhijiang Zhuang Liang Geng G E Wang Yun Cui Tongde Tian Sheng Wang Bian Shi Source Type: research
Risk stratification of invasive cervical cancer diagnosed after cervical conization
CONCLUSION: HPV16 positivity and nulliparity were identified as risk factors for undetected ICC. Careful treatment selection and preoperative scrupulous examination are especially important in these cases.PMID:37681246 | DOI:10.1093/jjco/hyad121
Source: Cancer Control - September 8, 2023 Category: Cancer & Oncology Authors: Tomoka Shiga Ayumi Taguchi Mayuyo Mori Shogo Yamaguchi Harunori Honjoh Akira Nishijima Satoko Eguchi Yuichiro Miyamoto Kenbun Sone Kei Kawana Yutaka Osuga Source Type: research
Prevalence of human papillomavirus infection in abnormal pap smears
CONCLUSION: Our study shows that the percentage of HR-HPV-positive case increases with the severity of cytologic morphology. HPV had 4 times higher positivity in squamous intraepithelial lesion as compared to ASCUS.PMID:37681080 | PMC:PMC10481853 | DOI:10.25259/Cytojournal_8_2021
Source: Cancer Control - September 8, 2023 Category: Cancer & Oncology Authors: Jaya Mishra Sweety Kalantri Vandana Raphael Biswajit Dey Yookarin Khonglah Ananya Das Source Type: research
A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer
Nat Commun. 2023 Sep 6;14(1):5195. doi: 10.1038/s41467-023-40798-6.ABSTRACTPancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy in need of new therapeutic options. Using unbiased analyses of super-enhancers (SEs) as sentinels of core genes involved in cell-specific function, here we uncover a druggable SE-mediated RNA-binding protein (RBP) cascade that supports PDAC growth through enhanced mRNA translation. This cascade is driven by a SE associated with the RBP heterogeneous nuclear ribonucleoprotein F, which stabilizes protein arginine methyltransferase 1 (PRMT1) to, in turn, control the translational mediator u...
Source: Cancer Control - September 6, 2023 Category: Cancer & Oncology Authors: Corina E Antal Tae Gyu Oh Stefan Aigner En-Ching Luo Brian A Yee Tania Campos Herv é Tiriac Katherine L Rothamel Zhang Cheng Henry Jiao Allen Wang Nasun Hah Elizabeth Lenkiewicz Jan C Lumibao Morgan L Truitt Gabriela Estepa Ester Banayo Senada Bashi Edga Source Type: research
New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & amp; therapeutics
Front Oncol. 2023 Aug 17;13:1193736. doi: 10.3389/fonc.2023.1193736. eCollection 2023.ABSTRACTProstate adenocarcinoma accounts for more than 20% of deaths among males due to cancer. It is the fifth-leading cancer diagnosed in males across the globe. The mortality rate is quite high due to prostate cancer. Despite the fact that advancements in diagnostics and therapeutics have been made, there is a lack of effective drugs. Metabolic pathways are altered due to the triggering of androgen receptor (AR) signaling pathways, and elevated levels of dihydrotestosterone are produced due to defects in AR signaling that accelerate th...
Source: Cancer Control - September 4, 2023 Category: Cancer & Oncology Authors: Neha Thakur Sameer Quazi Bindu Naik Saurabh Kumar Jha Pallavi Singh Source Type: research
Identification of cancer stemness and M2 macrophage-associated biomarkers in lung adenocarcinoma
CONCLUSION: Our study identified CBFA2T3 and DENND3 as key genes associated with mRNAsi and M2 macrophages in LUAD and investigated the potential molecular mechanisms underlying this relationship.PMID:37662825 | PMC:PMC10472008 | DOI:10.1016/j.heliyon.2023.e19114
Source: Cancer Control - September 4, 2023 Category: Cancer & Oncology Authors: XiaoFang Wang Xuan Luo ZhiYuan Wang YangHao Wang Juan Zhao Li Bian Source Type: research
Autotaxin suppresses cytotoxic T cells via LPAR5 to promote anti-PD-1 resistance in non-small cell lung cancer
J Clin Invest. 2023 Sep 1;133(17):e163128. doi: 10.1172/JCI163128.ABSTRACTNon-small cell lung cancers that harbor concurrent KRAS and TP53 (KP) mutations are immunologically warm tumors with partial responsiveness to anti-PD-(L)1 blockade; however, most patients observe little or no durable clinical benefit. To identify novel tumor-driven resistance mechanisms, we developed a panel of KP murine lung cancer models with intrinsic resistance to anti-PD-1 and queried differential gene expression between these tumors and anti-PD-1-sensitive tumors. We found that the enzyme autotaxin (ATX), and the metabolite it produces, lysoph...
Source: Cancer Control - September 1, 2023 Category: Cancer & Oncology Authors: Jessica M Konen B Leticia Rodriguez Haoyi Wu Jared J Fradette Laura Gibson Lixia Diao Jing Wang Stephanie Schmidt Ignacio I Wistuba Jianjun Zhang Don L Gibbons Source Type: research
Management of diarrhea induced by EGFR-TKIs in advanced lung adenocarcinoma
Ther Adv Med Oncol. 2023 Aug 24;15:17588359231192396. doi: 10.1177/17588359231192396. eCollection 2023.ABSTRACTThe identification of Epidermal Growth Factor Receptor (EGFR) mutations in lung adenocarcinoma has facilitated the development of personalized medicine based on oncogenic drivers. EGFR-Tyrosine Kinase Inhibitors (TKIs) are part of the targeted therapy; they impede the phosphorylation of the intracellular tyrosine kinase component of EGFR and consequently block signal transduction pathways. These drugs inhibit the proliferation and survival of tumor cells, leading to long-term progression-free survival and overall ...
Source: Cancer Control - September 1, 2023 Category: Cancer & Oncology Authors: Daniela C árdenas-Fernández Pamela Soberanis Pina Jenny G Turcott Norberto Ch ávez-Tapia Emilio Conde-Flores Andr és F Cardona Oscar Arrieta Source Type: research
